Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company advancing innovative treatments for cancer and diabetes, announced that Gabrail Cancer Center in Canton, Ohio has been added as a new site for its Acclaim-1 and Acclaim-3 clinical trials evaluating the company’s lead candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), for lung cancer. The company also noted that several additional trial sites are expected to launch in the coming months, aiming to broaden patient access and accelerate enrollment across the Acclaim program.
This expansion is part of Genprex’s broader plan to boost access for eligible patients, accelerate enrollment, and expedite timeline targets. The company expects to open further sites in the coming months.
The ACCLAIM-1 trial combines REQORSA with Tagrisso (osimertinib) for patients with EGFR-mutated NSCLC whose disease progressed after Tagrisso therapy. The trial’s Phase 2a expansion will enroll roughly 33 patients; interim analysis is planned after 19 patients receive treatment.
Meanwhile, ACCLAIM-3 is evaluating REQORSA plus Tecentriq (atezolizumab) as maintenance therapy for ES-SCLC patients who responded to initial standard treatment. The Phase 1 dose-escalation portion has been completed without dose-limiting toxicities, and Phase 2 expansion is ongoing.
Genprex CEO emphasized that adding new trial sites like Gabrail will broaden patient access and may accelerate trial completion, a critical factor for bringing novel gene therapies to patients quicker.
Unlock comprehensive NSCLC market trends, explore epidemiology trends, patient insights, emerging therapies, and competitive landscape shaping growth through 2034. Download the full report now.
How a DelveInsight Report Can Help Stakeholders
DelveInsight is known for producing detailed market-research reports that combine epidemiology, disease-burden estimates, competitive-landscape analysis, and market forecasts. For lung cancer especially EGFR-mutant NSCLC and ES-SCLC a DelveInsight report could provide:
- Accurate Epidemiology & Patient Population Estimates: Data on incidence, prevalence, and demographic/geographic breakdowns to gauge addressable patient pools for REQORSA therapy.
- Market Sizing & Forecasting: Projections of future treatment uptake, market penetration, and growth opportunities for novel therapies through 2030 and beyond.
- Competitive Landscape & Unmet Needs Analysis: Insights into existing standard-of-care, emerging therapies, and gaps that REQORSA could fill.
- Adoption & Reimbursement Scenarios: Evaluation of payer dynamics, pricing pressures, and likely commercial uptake in different regions.
- Strategic Planning Support for Investors & Developers: Helping pharma companies or investors decide on resource allocation, launch timing, and potential ROI based on robust data rather than assumptions.
Thus, by integrating Genprex’s clinical developments with DelveInsight’s rigorous market intelligence, stakeholders get a comprehensive view — from clinical promise to commercial potential.
Conclusion:
The addition of a new clinical site for ACCLAIM-1 and ACCLAIM-3 trials marks a strategic expansion by Genprex aimed at accelerating enrollment and enabling broader patient access to its REQORSA gene therapy for lung cancer. As these trials progress, combining the real-world clinical data with comprehensive market insight from a DelveInsight report will be critical providing context on patient populations, market demand, and commercial feasibility. This dual approach can help bridge the gap between scientific innovation and tangible impact for patients and investors alike.
